I do not think we have any good data on that. But statin certainly decrease the risk of IHD which is one of the leading cause of death in this group of patients.

I would suggest mostly through its pleiotropic (extralipid) effects - immunomodulatory, antioxidative effects, possibly.

Faiq, try this (fulltext currently online):

http://www.ncbi.nlm.nih.gov/pubmed/24658835

I recommend you this review:

Lopez-Pedrera C, Ruiz-Limon P, Valverde-Estepa A, Barbarroja N, Rodriguez-Ariza A. To cardiovascular disease and beyond: new therapeutic perspectives of statins in autoimmune diseases and cancer. Curr Drug Targets. 2012 Jun;13(6):829-41. Review. PMID: 22250652 [PubMed - indexed for MEDLINE]

This is from a group with vast experience in statins in lupus and APS.

Dear Patompong Ungprasert ,  Jana Rathouska,  Maria Laura Bertolaccini 

Thanks a lot for your answers.

It has  immunomodulatory, antioxidative effects and reduce risk of accelerated aterosclerosis

In APS, here it is another article:  Erkan D, Willis R, Murthy VL, Basra G, Vega J, Ruiz-Limón P, Carrera AL, Papalardo E, Martínez-Martínez LA, González EB, Pierangeli SS. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. 13 Aug 9. doi: 10.1136/ Ann Rheum Dis-2013-203622. PMID:23933625. 

Thanks a lot Aleksndra and Emilio for your answers. Best regards

Stations have immunomodulatary effects. Although it has been shown in RA previously, their effect on SLE activity is a matter of debate. Kindly see my original article entitled:"Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial." which published in Clinical Rheumatology, 2014,Sep.

Thanks a lot Alimohammad for your answer.